Order online in 2 minutes, visit a local lab same day, and get results in 1-3 days. No doctor's order needed.
Thyroid cancer is one of the most curable cancers, with a five-year survival rate exceeding 98% for localized cases today. This guide from mylabpanel.com explains the cure rates by type, stage, and the latest treatment options, helping you understand prognosis and next steps for monitoring your thyroid health.
Curability depends heavily on the specific thyroid cancer type. Papillary thyroid cancer, the most common (about 80% of cases), has a near-perfect cure rate when caught early. Follicular thyroid cancer also responds well, while medullary and anaplastic types have lower survival rates. Today, advances in targeted therapies and genetic profiling have improved outcomes even for aggressive forms.
For papillary and follicular cancers, the 10-year survival rate is 90–95%. Standard treatment includes surgical removal of the thyroid (thyroidectomy) followed by radioactive iodine therapy to destroy remaining tissue. Regular monitoring with blood tests for thyroglobulin and imaging ensures early detection of recurrence.
Medullary thyroid cancer (MTC) has a 10-year survival rate of about 75% for localized disease. Anaplastic thyroid cancer (ATC) is rare but aggressive, with a median survival of 6 months; however, new immunotherapies and targeted drugs in clinical trials today are improving these numbers. Early detection through genetic testing and imaging is critical.
Below is a summary of five-year relative survival rates for thyroid cancer in the United States, based on SEER data and clinical guidelines from the American Thyroid Association.
| Thyroid Cancer Type | Localized (Stage I–II) | Regional (Stage III) | Distant (Stage IV) |
|---|---|---|---|
| Papillary | 99.9% | 98% | 75% |
| Follicular | 99% | 95% | 65% |
| Medullary | 95% | 80% | 40% |
| Anaplastic | 20% | 10% | <5% |
Today, the standard of care for thyroid cancer includes liquid biopsies to detect circulating tumor DNA, allowing earlier detection of recurrence. Targeted therapies like selpercatinib for RET-mutated MTC and dabrafenib/trametinib for BRAF-mutated ATC have extended survival. Radioactive iodine remains a mainstay, but newer isotopes with fewer side effects are under FDA review. Regular thyroid function tests and tumor marker panels are essential for long-term monitoring—and mylabpanel.com offers convenient at-home lab testing to track these markers.
If you have a family history of thyroid cancer, a lump in your neck, or unexplained hoarseness, testing for thyroglobulin, calcitonin, and RET mutations can aid early diagnosis. For those already treated, periodic monitoring with these biomarkers helps confirm remission. mylabpanel.com’s thyroid panel provides comprehensive results you can review with your physician.
Take control of your thyroid health today. Order our complete Thyroid Cancer Monitoring Panel from mylabpanel.com—no doctor’s visit required, fast results, and secure online reports.
Ready to order your test?
Order online in 2 minutes and visit a local lab same day.
Find a Lab Near MeFor localized papillary and follicular thyroid cancer, the five-year survival rate exceeds 98% today. Medullary and anaplastic types have lower rates, but new targeted therapies are improving outcomes.
Yes, recurrence occurs in about 10–20% of cases within 10 years. Regular monitoring with blood tests (thyroglobulin, calcitonin) and imaging is essential for early detection.
Surgery is the primary curative treatment for most thyroid cancers. Radioactive iodine and targeted drugs are used as adjuvant therapy, but they are not standalone cures for invasive disease.
Affiliate disclosure: MyLabPanel may earn a commission when you book a test through links on this page, at no extra cost to you.